Levine Cancer

It’s a game changer in the fight against cancer – but what is proton beam therapy and how does it work? Watch this to learn more about this highly precise treatment option for kids and adults with complex diagnoses.

👏👏👏

Congratulations to our very own @b_avalos_MD on a successful year serving as the president of @ASH_hematology. Your leadership and dedication have advanced hematology and inspired so many. 👏🎉#ASH25

A new multi-center study shows autologous stem cell boost (SCB) is safe and speeds recovery for CAR-T. Patients had higher hemoglobin & platelets by day 90. #ASH25 Link to the study: bit.ly/3Kk3m1b

New study shows dexamethasone can safely manage low-grade CRS in patients on talquetamab for relapsed/refractory multiple myeloma for management. #ASH25 Read more about the outcomes: bit.ly/4iHn5nX

Our researchers compared two drug combos for large B-cell lymphoma after other treatments failed. Mosunetuzumab + polatuzumab proved more effective. #ASH25 Link: bit.ly/48nNrbd

Big #ASH25 news: Aza-Ven combo for AML patients offers improved event-free survival & better quality of life versus conventional intensive chemo. A gentler, more effective standard may shift the paradigm of care. @BKRagonMD was one of the investigators: bit.ly/3MBQDY8

A promising step toward early intervention. Prenatal therapy using engineered placental cells delivered FVIII before birth—turning severe hemophilia A into a mild form in animal models. #ASH25 Read more: bit.ly/48mP0Gq

Improving care for sickle cell patients🩸 Targeted triage education boosted high-priority assignments for painful VOE ensuring faster pain relief and better ED outcomes. #ASH25 Link: bit.ly/4oXz2I1

A new tool for MPN patients 🩸🔧Dr. Mesa (@mpndrc) presented research showing the MPN Journal helps track symptoms, treatments & lifestyle factors - empowering patients & improving care. #ASH25 Link: bit.ly/3KMbY0y

Celebrating our cancer leader Dr. Ruben Mesa (@mpndrc) as he receives the prestigious Ernest Beutler Lecture & Prize at #ASH25! His lecture spotlights his translational research on JAK inhibitors and how they’ve transformed care for MPN patients. Congratulations! 🎉🩸

Dissecting why older AML patients struggle with treatment 🩸 Our researchers discovered leukemia cells arising in older patients have a messy epigenome from years of DNA repair. This chaos makes the disease more resistant and harder to kill. #ASH25 Link: bit.ly/44NhlDp

Study Alert: L-carnitine shows no benefit in preventing or treating liver toxicity from pegylated asparaginase in adults with ALL. Retrospective analysis across 5 centers found no improvement in bilirubin or ALT recovery. #ASH25 Link: bit.ly/3XIM3Kd

New research shows promise for treating genetic blood disorders before birth. Using targeted antibody-drug conjugates, scientists boosted stem cell engraftment in fetal models—paving the way for safer, in-utero therapies. @wakeforestmed #ASH25 👉 bit.ly/4pnBc4F

New real-world study shows: Despite many treatment options, outcomes for #MultipleMyeloma patients who relapse after lenalidomide remain poor. More effective solutions are urgently needed. #ASH25 👉 bit.ly/48yDF4R

New insight 💡 MGUS can do more than signal plasma cell disorders—it may trigger Acquired Hemophilia A, a rare autoimmune attack on Factor VIII causing severe bleeding. Heightened vigilance is key. #ASH25 Link: bit.ly/4psw2UU

New study shows multiple myeloma patients who relapse within 30 months of starting treatment face significantly worse outcomes—even without classic high-risk markers. Identifying these “functional high-risk” patients is critical for better care. #ASH25 👉 bit.ly/3XEKFbA

Our researchers discovered silver nanoparticles (AgNPs) kill multiple myeloma cancer cells—even those resistant to bortezomib—and work synergistically with the drug. @wakeforestmed #ASH25 👉 bit.ly/4pgseGa

Prenatal gene therapy for Hemophilia A shows promise! 🧬🐑 In a sheep study, delivering AAV-based therapy before birth led to sustained FVIII levels for a year—far better than postnatal treatment. @wakeforestmed #ASH25 👉 bit.ly/48UNuLP

After stem cell transplant for #MultipleMyeloma, most patients gain strong protection vs serious pneumococcal infections—but intensive regimens like daratumumab can slow vaccine response. #ASH25 @AtriumHealthWFB Link: bit.ly/4oFgmwe

Data from voxelotor use offers critical insights: significant gains in hemoglobin and reduced hemolysis for sickle cell patients. This knowledge will guide future therapies toward better outcomes. #ASH25 Read more: bit.ly/48kLTyM